<DOC>
	<DOCNO>NCT00019175</DOCNO>
	<brief_summary>RATIONALE : Vaccines make antigen combine modify virus may make body build immune response kill tumor cell . Interleukin-2 may stimulate person 's white blood cell kill melanoma cell . Combining vaccine therapy interleukin-2 may kill tumor cell . PURPOSE : Phase I trial compare effectiveness vaccine therapy without interleukin-2 treating patient recurrent metastatic melanoma respond previous therapy .</brief_summary>
	<brief_title>Vaccine Therapy With Without Interleukin-2 Treating Patients With Recurrent Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate toxicity , immunologic reactivity , possible therapeutic efficacy immunization recombinant fowlpox virus encode gp100 melanoma antigen administer alone interleukin-2 patient metastatic melanoma . OUTLINE : This dose-escalation study . Patients receive recombinant fowlpox virus encode gp100 melanoma antigen ( FPV-gp100 ) IV intramuscularly rotate site fowlpox virus encode modify gp100 melanoma antigen IV every 2 week 4 vaccination . Treatment continue maximum 2 course absence disease progression . Cohorts 3-9 patient receive escalate dos FPV-gp100 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient develop dose-limiting toxicity . Patients 3 5 cohort also receive interleukin-2 ( IL-2 ) within 12 hour FPV-gp100 . One cohort receive IL-2 subcutaneously daily day 1-5 day 8-12 . A second cohort receive low-dose IL-2 IV 15 minute every 8 hour day 2-8 . A third cohort receive high-dose IL-2 IV 15 minute every 8 hour day 2-6 . Patients cohorts 4 5 receive FPV-gp100 alone , response observe 2 course , may receive 2 course IL-2 alone every 8 hour 5 day , approximately 2 week apart . A separate cohort 3-9 patient receives modify FPV-gp100 . If response observe 2 course , IL-2 may administer cohort 4 5 . Patients follow 28 day second immunization FPV-gp100 . PROJECTED ACCRUAL : A maximum 91 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma fail standard therapy Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : WBC great 3,000/mm3 Platelet count great 100,000/mm3 Hemoglobin great 8.0 g/dL No coagulation disorder Hepatic : Bilirubin great 2.0 mg/dL AST ALT less 4 time normal Hepatitis B negative Renal : Creatinine great 1.6 mg/dL Cardiovascular : No major cardiovascular disease Pulmonary : No major respiratory disease Other : HIV negative No major immunologic illness No eczema No hypersensitivity egg No active systemic infection No psoriasis Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics More 20 day since prior therapy No concurrent steroid therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>